Similar Search Results

Use of Healthcare Services by Patients Treated with Risperidone Versus Conventional Antipsychotic Agents

Gianfrancesco, Frank; Durkin, Michael B.; Mahmoud, Ramy; … - In: PharmacoEconomics 20 (2002) 6, pp. 413-427

hospitalisation costs. This indicates that risperidone may be a more economical choice than traditional antipsychotics for the …Objective: To determine whether the use of risperidone in a US managed-care environment is associated with a reduction … treated with risperidone versus those treated with conventional antipsychotic agents were compared by both between-group and …

Persistent link: https://www.econbiz.de/10005590323

Cost Analysis of the Treatment of Schizophrenia in the UK: A Simulation Model Comparing Olanzapine, Risperidone and Haloperidol

Almond, Stephen; O'Donnell, Owen - In: PharmacoEconomics 17 (2000) 4, pp. 383-389

Objective: To compare the costs of 2 atypical drug therapies (olanzapine and risperidone) with one another and with a … conventional antipsychotic (haloperidol) in the treatment of schizophrenia. Design and setting: The analysis is based on a … simulation model with parameter values taken mainly from clinical trial data in patients with schizophrenia, and was conducted …

Persistent link: https://www.econbiz.de/10005243166

Direct Costs of Schizophrenia in Italian Community Psychiatric Services

Garattini, Livio; Rossi, Carlotta; Tediosi, Fabrizio; … - In: PharmacoEconomics 19 (2001) 12, pp. 1217-1225

Objective: To estimate resource utilisation and direct costs of treatment for patients with schizophrenia in Italian … National Health Service (INHS). Patients: 702 patients with a diagnosis of schizophrenia or other psychotic disorders, defined …: The mean direct cost of patients with schizophrenia in the 2-month observation period was 2 234 475 Italian lire [L] (1154 …

Persistent link: https://www.econbiz.de/10005449030

Cost Analysis of the Treatment of Schizophrenia in the UK: A Comparison of Olanzapine and Haloperidol

Almond, Stephen; O'Donnell, Owen - In: PharmacoEconomics 13 (1998) 5, pp. 575-588

treatment of patients with schizophrenia in the UK. Parameter values and outcome scores were derived mainly from an …

Persistent link: https://www.econbiz.de/10005404938

Patient Compliance with Drug Therapy in Schizophrenia: Economic and Clinical Issues

Lindstrom, Eva; Bingefors, Kerstin - In: PharmacoEconomics 18 (2000) 2, pp. 105-124

individuals with schizophrenia and intolerable adverse effects. There has long been a need for new antipsychotics that can … routine clinical practice would be a significant advantage in the treatment of schizophrenia, one of the most costly diseases … in society. The aetiology of schizophrenia is unknown, and there is no cure. The main aims of therapy with antipsychotic …

Persistent link: https://www.econbiz.de/10005590347

Preventing Relapse of Psychotic Illness: Role of Self-Monitoring of Prodromal Symptoms

Hewitt, Lisa; Birchwood, Max - In: Disease Management and Health Outcomes 10 (2002) 7, pp. 395-407

The consequences of psychotic relapse have been found to be damaging to both psychiatric clients and their families, as well as having a detrimental effect on the financial resources of mental health services. As a result of these findings, it is viewed that effective relapse prevention should...

Persistent link: https://www.econbiz.de/10005448828

Costs of Bipolar Disorder

Kleinman, Leah S.; Lowin, Ana; Flood, Emuella; Gandhi, Gian - In: PharmacoEconomics 21 (2003) 9, pp. 601-622

Bipolar disorder is a chronic affective disorder that causes significant economic burden to patients, families and society. It has a lifetime prevalence of approximately 1.3%. Bipolar disorder is characterised by recurrent mania or hypomania and depressive episodes that cause impairments in...

Persistent link: https://www.econbiz.de/10005404937

Cost Effectiveness of Long-Acting Risperidone in Sweden

Hensen, Marja; Heeg, Bart; Lothgren, Mickael Lthgren; … - In: Applied Health Economics and Health Policy 8 (2010) 5, pp. 327-341

Background: In Sweden, risperidone long-acting injectable (RLAI) is generally used in a population of schizophrenia … schizophrenia population. Objectives: To analyse the clinical and economic effects of RLAI in the Swedish treatment practice using a …-compliant patient population and the general schizophrenia population. Methods: An existing DES model was adapted to simulate the …

Persistent link: https://www.econbiz.de/10008506287

Cost-Effectiveness Analysis of Switching Antipsychotic Medication to Long-Acting Injectable Risperidone in Patients with Schizophrenia: A 12- and 24-Month Follow-Up from the e-STAR...

Olivares, Jose M.; Rodriguez-Martinez, Alfonso; Buron, … - In: Applied Health Economics and Health Policy 6 (2008) 1, pp. 41-53

Background: The availability of long-acting injectable risperidone may increase adherence to antipsychotic treatment … and lead to improved clinical and economic outcomes for patients with schizophrenia. Objectives: To investigate the cost … effectiveness of treatment with long-acting injectable risperidone compared with previous antipsychotic regimens in patients with …

Persistent link: https://www.econbiz.de/10005590254

Association of Co-Morbidities with Prescribing Patterns and Cost Savings: Olanzapine versus Risperidone for Schizophrenia

Yu, Wei; Ren, Xinhua S.; Lee, Austin F.; Herz, Lawrence; … - In: PharmacoEconomics 24 (2006) 12, pp. 1233-1248

Background: Olanzapine and risperidone are two commonly prescribed atypical antipsychotics for schizophrenia. Prior …_499 patients with schizophrenia prescribed either olanzapine or risperidone between 1 April 1999 and 31 March 2000 we defined … study analysed the cost effects of olanzapine and risperidone among those who had intensive utilisation of medical care …

Persistent link: https://www.econbiz.de/10005590398